Foundation Medicine and PMV Pharma are excited to announce our partnership to develop a companion diagnostic for rezatapopt, an innovative first-in-class selective p53 Y220C reactivator. This collaboration leverages Foundation Medicine’s FoundationOne®CDx, a comprehensive genomic profiling test, to identify patients with TP53 Y220C mutations who may benefit from this novel therapy. For more information, visit Foundation Medicine and PMV Pharmaceuticals, Inc. #CancerResearch #PrecisionMedicine #Oncology #GenomicProfiling #CancerTreatment #TP53 #FoundationMedicine #PMVPharma #Rezatapopt #InnovationInHealth
PMV Pharmaceuticals, Inc.’s Post
More Relevant Posts
-
A very interesting poster entitled "A Quantitative Systems Pharmacology model of head and neck squamous cell carcinoma: a tool for evaluating treatment outcomes for combination therapies" was presented by Oleg Demin and Alexandra Diakonova at #SITC2023. Monotherapies and combinations of cetuximab, pembrolizumab, and various chemotherapies were described in the model. The work was done in collaboration with colleagues from Genmab. Great work by Oleg, Alexandra, and co-authors: Sergey Smirnov, Anna Roskoshnaia, Ivan Borisov, Gaurav Bajaj, Homer Adams III, Ph.D., Maria Jure-Kunkel, Manish Gupta, Craig Thalhauser. You can find other InSysBio posters from recent conferences here: https://lnkd.in/g3xtwKXJ #modelingandsimulation #MID3 #QSP #biopharma #biopharmaceuticals #cancer #cancertreatment #immunooncology #immunotherapy #oncology #pharma #biotech #SITC23 InSysBio
-
New DUB inhibitor: Deubiquitinating enzymes or DUBs, are proteases that regulate ubiquitination dynamics. DUBs have become promising targets for drug discovery across diverse therapeutic areas. (for a review see https://lnkd.in/eWF8X2CQ) Recently Zhang and coworkers reported the identification of OTUDin3 as a potent inhibitor of OTUD3, a DUB which promotes lung tumorigenesis by stabilizing oncoprotein GRP78. OTUDin3 displayed pronounced antiproliferative effects and suppressed the growth of lung cancer xenografts in mice. https://lnkd.in/ecMuqGs9 Focus Biomolecules offers OTUDin3 for research applications. For more information visit: https://lnkd.in/ejnR3rQC #Ubiquitin #smallmolecules #cancerresearch #pharmacology
-
-
A special issue on the "Roles of MET in Cancer Development and Treatment" has just been published by Cancers, with Jens Mollerup and Jan Trøst Jørgensen as Guest Editors. The special issue can be downloaded free of charge from: https://lnkd.in/eVsxQgck #medicine #pharmaceuticals #oncology #pharmacology #precisionmedicine
-
-
November is Pancreatic Cancer Awareness Month, and we recognize the importance of precision medicine in the fight against pancreatic ductal adenocarcinoma. Patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models are valuable tools in evaluating the therapeutic efficacy of new anti-cancer therapies through preclinical studies, including drug screening, pharmacokinetic and pharmacodynamics assessments, and toxicity detection. They can help advance research by providing information about tumorigenesis, metastasis and recurrence and a system to generate valuable predictive data to help guide personalized treatment, which may lead to improved clinical management. Speak with one of our experts to determine which studies will help advance your program. Click the following link to learn more, https://lnkd.in/dqfqDp8 #PancreaticCancerAwareness #cancerresearch #personalizedtherapies #translationalcancerresearch #GD3services
-
November is Pancreatic Cancer Awareness Month, and we recognize the importance of precision medicine in the fight against pancreatic ductal adenocarcinoma. Patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models are valuable tools in evaluating the therapeutic efficacy of new anti-cancer therapies through preclinical studies, including drug screening, pharmacokinetic and pharmacodynamics assessments, and toxicity detection. They can help advance research by providing information about tumorigenesis, metastasis and recurrence and a system to generate valuable predictive data to help guide personalized treatment, which may lead to improved clinical management. Speak with one of our experts to determine which studies will help advance your program. Click the following link to learn more, https://lnkd.in/dqfqDp8 #PancreaticCancerAwareness #cancerresearch #personalizedtherapies #translationalcancerresearch #GD3services
-
November is Pancreatic Cancer Awareness Month, and we recognize the importance of precision medicine in the fight against pancreatic ductal adenocarcinoma. Patient-derived xenograft (PDX) and cell line-derived xenograft (CDX) models are valuable tools in evaluating the therapeutic efficacy of new anti-cancer therapies through preclinical studies, including drug screening, pharmacokinetic and pharmacodynamics assessments, and toxicity detection. They can help advance research by providing information about tumorigenesis, metastasis and recurrence and a system to generate valuable predictive data to help guide personalized treatment, which may lead to improved clinical management. Speak with one of our experts to determine which studies will help advance your program. Click the following link to learn more, https://lnkd.in/dqfqDp8 #PancreaticCancerAwareness #cancerresearch #personalizedtherapies #translationalcancerresearch #GD3services
Experienced and Versatile Medical Affairs Leader // Strong Foundations Elevate Success
1moCongratulations and best of luck!